Despite the dispersion, Figures 3 and 4 indicate an increasing trend with respect to the apixaban peak and trough serum concentration for patients co‐administered apixaban, diltiazem and a statin (atorvastatin or rosuvastatin).
← all excerpts
Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
1
—
—